Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.

@article{Mark1995CostEO,
  title={Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.},
  author={Daniel B. Mark and Mark A. Hlatky and Robert M. Califf and C. David Naylor and Kerry L. Lee and Paul Wayne Armstrong and Gabriel I. Barbash and Hugh White and Maarten L. Simoons and Charlotte L. Nelson},
  journal={The New England journal of medicine},
  year={1995},
  volume={332 21},
  pages={1418-24}
}
BACKGROUND Patients with acute myocardial infarction who were treated with accelerated tissue plasminogen activator (t-PA) (given over a period of 1 1/2 hours rather than the conventional 3 hours, and with two thirds of the dose given in the first 30 minutes) had a 30-day mortality that was 15 percent lower than that of patients treated with streptokinase in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) study. This was equivalent… CONTINUE READING